In the ever-evolving field of diabetes management, incretin mimetics have emerged as a transformative therapeutic class. Among these, retaglutide, retatrutide, and trizepatide represent novel additions to the arsenal https://tiffanyrncl053498.mybloglicious.com/58994444/novel-glp-1-receptor-agonists-retaglutide-retatrutide-and-trizepatide